Table 1.
Phase II studies | Chemotherapy regimen | n | Time to progression (months) | Response rate | Median survival (months) |
---|---|---|---|---|---|
Kabbinavar et al47 | 5-FU/LV | 36 | 5.2 | 6 (17%) | 13.8 |
5-FU/LV + BV 5 mg/kg | 35 | 9 | 14 (40%) | 21.5 | |
5-FU/LV + BV 10 mg/kg | 33 | 7.2 | 8 (24%) | 16.1 | |
Kabbinavar et al57 | 5-FU/LV | 105 | 5.5 | 15.2% | 12.9 |
5-FU/LV + BV 5 mg/kg | 104 | 9.2 | 26% | 16.6 |
Abbreviation: BV, bevacizumab.